Last updated: September 14, 2026
Olaratumab, marketed as Lartruvo by Eli Lilly, generated rapid sales after its accelerated FDA approval in October 2016 but lost its commercial market after the confirmatory ANNOUNCE trial failed to verify clinical benefit. The FDA withdrew approval in June 2019, and Lilly discontinued global commercialization. Olaratumab has no active U.S. commercial market, no established generic or biosimilar launch pathway, and limited residual value outside historical litigation, regulatory, and clinical-development analysis.
What was olaratumab approved to treat?
Olaratumab was a recombinant human monoclonal antibody targeting platelet-derived growth factor receptor alpha, or PDGFR-alpha. The FDA approved it in combination with doxorubicin for adults with advanced soft-tissue sarcoma that was not amenable to curative surgery or radiotherapy and for which an anthracycline-containing regimen was appropriate.
The October 2016 approval used the accelerated approval pathway. The pivotal basis was a randomized phase 2 study showing a progression-free survival and overall-survival signal in patients treated with olaratumab plus doxorubicin compared with doxorubicin alone. The regimen was not approved as monotherapy.
| Item |
Olaratumab status |
| Brand |
Lartruvo |
| Active ingredient |
Olaratumab |
| Developer and marketer |
Eli Lilly and Company |
| Target |
PDGFR-alpha |
| Initial FDA approval |
October 19, 2016 |
| FDA pathway |
Accelerated approval |
| Indication |
Advanced soft-tissue sarcoma |
| Combination partner |
Doxorubicin |
| Dosage form |
Intravenous infusion |
| Confirmatory trial |
ANNOUNCE, phase 3 |
| U.S. approval status |
Withdrawn |
| Current commercial status |
Discontinued |
The approval was unusual because the confirmatory trial failed to reproduce the earlier survival result. That failure eliminated the clinical and commercial foundation of the product.
When did olaratumab lose exclusivity and market access?
Olaratumab lost market access before ordinary patent or biologic exclusivity expiration. Lilly announced in January 2019 that ANNOUNCE had failed to meet its primary overall-survival endpoint in the overall soft-tissue-sarcoma population and in the leiomyosarcoma subgroup. Lilly and regulators advised against starting new patients.
The FDA later withdrew the approval. The European Medicines Agency recommended suspension of the marketing authorization, and the European Commission subsequently revoked the authorization in 2019.
| Date |
Event |
| October 2016 |
FDA grants accelerated approval for Lartruvo plus doxorubicin |
| 2017 |
Commercial launch expands in the United States and other markets |
| January 2019 |
Lilly reports negative ANNOUNCE results |
| January-February 2019 |
Regulators advise that new patients should not begin treatment |
| April 2019 |
EMA recommends suspension of the European authorization |
| June 2019 |
FDA withdraws U.S. approval |
| 2019 |
Lilly ends routine commercial supply and global commercialization |
The biologic exclusivity period did not determine the product’s market life. Under the Biologics Price Competition and Innovation Act, a reference biologic can receive 12 years of reference-product exclusivity from first licensure, subject to statutory limitations. Olaratumab’s commercial failure occurred roughly three years after approval, long before that period could have supported meaningful biosimilar competition.
What was the financial trajectory of Lartruvo?
Lartruvo had a short, steep revenue curve. Sales increased rapidly after launch because the product entered a high-unmet-need oncology market with an accelerated approval and a favorable early survival signal. Revenue then fell after the ANNOUNCE failure and regulatory withdrawal.
Eli Lilly’s annual reports identified Lartruvo as a product with material sales growth during the initial launch period. Reported sales were approximately:
| Fiscal year |
Approximate Lartruvo revenue |
Market interpretation |
| 2016 |
About $25 million |
Partial launch year |
| 2017 |
About $100 million |
Initial commercial adoption |
| 2018 |
About $300 million |
Peak commercial period |
| 2019 |
Sharp decline |
Withdrawal, treatment discontinuation, and inventory effects |
| 2020 onward |
No meaningful recurring commercial franchise |
Product discontinued |
The exact reported amount can differ depending on whether a source uses gross product revenue, net revenue, geographic presentation, or later accounting adjustments. The central financial pattern is clear: Lartruvo moved from launch-stage revenue to peak revenue in 2018, then suffered a rapid collapse after the confirmatory trial failure.
The revenue profile reflected several factors:
- The soft-tissue-sarcoma population was relatively small.
- The regimen was restricted to patients suitable for doxorubicin.
- Treatment required intravenous administration.
- The product depended on accelerated-approval evidence.
- The negative phase 3 result removed physician confidence and reimbursement support.
The product’s failure also affected Lilly’s pipeline economics. Development spending, manufacturing capacity, commercial infrastructure, medical-affairs activity, and inventory associated with the antibody had limited recoverable value after withdrawal.
What caused the collapse in olaratumab demand?
The ANNOUNCE trial was the decisive commercial event. The study did not confirm the overall-survival improvement observed in the phase 2 trial. It also failed to show the expected benefit in the leiomyosarcoma subgroup.
The study compared olaratumab plus doxorubicin with doxorubicin plus placebo. Its failure created three immediate commercial effects:
- Physicians stopped initiating new patients.
- Existing treatment decisions shifted toward established sarcoma regimens.
- Payers and hospitals lost a rationale for routine reimbursement and formulary support.
This was a clinical-risk failure rather than a conventional price or competitor-driven erosion event. Olaratumab did not lose share because a lower-priced generic or biosimilar entered the market. It lost its market because the benefit-risk case no longer supported treatment.
What is the FDA regulatory status of olaratumab?
The FDA approval is withdrawn. Lartruvo is not an FDA-approved treatment for soft-tissue sarcoma.
The original approval was conditioned on verification of clinical benefit in a post-approval trial. When ANNOUNCE failed, the accelerated-approval basis was no longer sustainable. The FDA’s withdrawal action closed the U.S. regulatory pathway for routine marketing under the original indication.
Olaratumab is therefore distinct from products that remain approved but face patent expiry. Its regulatory status prevents a conventional generic-launch scenario. A company cannot rely on an abbreviated new drug application to market a copy of a withdrawn biologic under the former approval framework.
What patents protected olaratumab?
Olaratumab was protected through a combination of biologic exclusivity, antibody-related patent rights, manufacturing know-how, and regulatory data rights. Because olaratumab was regulated as a biologic, it did not have a conventional Orange Book patent profile comparable to a small-molecule drug such as imatinib or pazopanib.
The primary protection categories were:
Antibody and antigen-binding patents
These rights may cover:
- Antibodies binding PDGFR-alpha;
- Specific antibody sequences;
- Complementarity-determining regions;
- Binding characteristics;
- Antibody variants and engineered forms.
Pharmaceutical composition and formulation patents
Potential claim areas include:
- Olaratumab compositions;
- Stabilized liquid formulations;
- Buffer systems;
- Concentration ranges;
- Container and storage conditions;
- Intravenous administration preparations.
Manufacturing and process rights
Manufacturing barriers may involve:
- Recombinant cell-line production;
- Cell-culture conditions;
- Purification steps;
- Viral-clearance processes;
- Quality-control assays;
- Aggregation control and potency testing.
Method-of-use rights
Method claims could cover use of an anti-PDGFR-alpha antibody with doxorubicin for soft-tissue sarcoma or related oncology settings. Such claims would have limited practical value after the confirmatory failure and withdrawal of the underlying indication.
A precise patent-by-patent expiration analysis requires verified patent-family records and claim-status review. Public regulatory materials establish the approval, withdrawal, and biologic-exclusivity framework, but they do not create an Orange Book-style consolidated list for all biologic patent rights.
What is the Orange Book status of olaratumab?
Olaratumab does not have a conventional Orange Book patent-listing position. Lartruvo was regulated as a biologic product, and biologic reference-product protection is handled through the BPCIA framework rather than the standard small-molecule Orange Book pathway.
The practical implications are:
- No conventional Orange Book Paragraph IV certification strategy;
- No standard ANDA-based generic substitution pathway;
- No routine small-molecule patent-stay analysis under Hatch-Waxman;
- Any follow-on product would need to proceed through a biologic or full-license pathway;
- Withdrawal of the reference product’s approval eliminates the ordinary commercial basis for a biosimilar launch.
Were there Paragraph IV challenges to olaratumab?
No commercially significant Paragraph IV challenge is associated with olaratumab. The product’s market ended before patent litigation could become a material driver of generic entry.
A Paragraph IV strategy would have been structurally inappropriate for a conventional biologic product. A follow-on sponsor would instead consider the BPCIA pathway, including reference-product exclusivity, patent-exchange procedures, and potential patent litigation under the biologic framework.
No known generic or biosimilar competitor reached the U.S. market before Lartruvo was withdrawn.
What biosimilar risk existed for olaratumab?
The practical biosimilar risk was low because regulatory failure eliminated the market before biosimilar development could mature. The theoretical exclusivity window was longer than the product’s actual commercial life.
A biosimilar sponsor would have faced several barriers:
| Barrier |
Commercial effect |
| Small soft-tissue-sarcoma population |
Limited addressable market |
| Combination with doxorubicin |
Complex clinical positioning |
| Failed confirmatory study |
Weak reference-product value |
| Withdrawn approval |
Uncertain regulatory and reimbursement pathway |
| Complex monoclonal-antibody manufacturing |
High development cost |
| Limited physician demand |
Poor return on biosimilar investment |
Olaratumab illustrates that long regulatory exclusivity does not guarantee durable commercial protection. Clinical validation is a prerequisite for maintaining value in an accelerated-approval oncology franchise.
Which companies challenged or replaced olaratumab?
No company displaced Lartruvo through a direct generic or biosimilar launch. Instead, the competitive set consisted of established soft-tissue-sarcoma treatments and clinical-trial options.
Relevant alternatives included:
- Doxorubicin-based chemotherapy;
- Ifosfamide-containing regimens;
- Gemcitabine and docetaxel;
- Trabectedin;
- Eribulin;
- Pazopanib;
- Clinical trials involving targeted agents and immunotherapies.
The closest commercial substitutes depended on histology, prior treatment, disease location, patient fitness, and treatment objective. Because olaratumab was withdrawn, competition shifted from product-level price competition to clinical substitution.
How strong was the olaratumab patent estate?
The patent estate may have provided meaningful technical and legal protection during the product’s short commercial period, but its economic strength was weakened by the failed clinical program.
Patent strength should be assessed across four dimensions:
| Dimension |
Assessment |
| Composition and antibody claims |
Potentially strong if sequence-specific and technically narrow |
| Formulation claims |
Potentially useful against copycat products using the same formulation |
| Method-of-use claims |
Commercially weakened by withdrawal of the approved indication |
| Manufacturing know-how |
Difficult to copy but less valuable without market demand |
The key distinction is between legal exclusivity and commercial exclusivity. Olaratumab may have retained patent or biologic protection after 2019, but those rights did not preserve revenue because the product no longer had regulatory or clinical support.
What generic launch scenarios existed for olaratumab?
The realistic launch scenarios were limited:
- No conventional generic launch under the ANDA pathway.
- No biosimilar launch before market withdrawal.
- Possible future development of an antibody against the same target under a separate regulatory strategy.
- Limited off-label or investigational use, subject to clinical and institutional decisions.
- No credible commercial opportunity without a new validated indication.
A follow-on company would need to establish a new clinical and regulatory value proposition. Patent clearance alone would not solve the central problem created by the negative ANNOUNCE result.
Did licensing deals affect olaratumab’s commercial value?
Olaratumab was developed and commercialized by Eli Lilly. No major external licensing transaction became a defining element of its commercial trajectory. The product originated from Lilly’s oncology development activities and was marketed through Lilly’s commercial infrastructure.
The lack of a large external transaction reduced the possibility of transferring the failed asset to a buyer seeking residual value. After the regulatory withdrawal, the asset’s value was primarily limited to:
- Archived clinical data;
- Manufacturing knowledge;
- Antibody technology;
- Potential research use;
- Historical evidence for accelerated-approval risk management.
What litigation affected olaratumab?
No major patent or commercial litigation drove the product’s market outcome. The primary event was regulatory and clinical, not judicial.
The relevant legal exposure centered on:
- The FDA’s withdrawal of approval;
- Product labeling and treatment guidance;
- Potential reimbursement disputes;
- Contractual and inventory matters following discontinuation;
- Any shareholder or securities claims arising from disclosure of trial results.
No sustained Hatch-Waxman litigation cycle developed because the product did not reach the point of conventional generic competition.
How does olaratumab compare with successful oncology biologics?
Olaratumab differed from durable oncology biologics in four ways:
| Factor |
Olaratumab |
Durable oncology biologics |
| Evidence base |
Accelerated approval followed by failed confirmation |
Confirmed benefit maintained |
| Indication breadth |
Narrow soft-tissue-sarcoma use |
Often multiple indications |
| Commercial scale |
Small specialty population |
Broader or expanding populations |
| Competitive durability |
Ended after clinical failure |
Extended through new indications and lifecycle management |
Products such as trastuzumab, pembrolizumab, and nivolumab expanded through multiple indications and sustained development programs. Olaratumab had no comparable lifecycle-management opportunity after ANNOUNCE failed.
What is the current commercial outlook for olaratumab?
The current commercial outlook is effectively zero for routine marketed sales. Olaratumab is a discontinued product with no active U.S. approval and no established biosimilar competition.
Its remaining relevance is analytical:
- It is a case study in accelerated-approval risk.
- It illustrates the difference between patent exclusivity and commercial durability.
- It demonstrates the financial impact of a negative confirmatory oncology trial.
- It remains relevant to valuation models for biologics with narrow indications.
- It provides a warning against treating early survival signals as durable franchise value.
Key Takeaways
- Olaratumab, marketed as Lartruvo, was FDA-approved in 2016 for advanced soft-tissue sarcoma with doxorubicin.
- Lilly’s sales rose from launch-stage revenue to approximately $300 million in 2018 before collapsing after the ANNOUNCE trial failed.
- The FDA withdrew approval in 2019, and Lilly discontinued global commercialization.
- No meaningful Paragraph IV litigation or biosimilar competition developed.
- Olaratumab did not follow a conventional Orange Book generic-erosion cycle.
- The product lost commercial value because of clinical failure, not because of patent expiry.
- Its patent and manufacturing rights may have remained legally relevant, but they could not preserve market demand.
- The asset has no current routine commercial franchise.
FAQs About Olaratumab
Is olaratumab still available in the United States?
No. The FDA withdrew approval, and Lilly discontinued routine commercial distribution.
Why did the FDA withdraw Lartruvo?
The FDA withdrew Lartruvo after the required ANNOUNCE confirmatory trial failed to verify the survival benefit supporting accelerated approval.
Did a generic version of olaratumab launch?
No conventional generic or biosimilar version achieved commercial launch before the product was withdrawn.
Was olaratumab a PDGFR inhibitor?
Olaratumab was a monoclonal antibody directed against PDGFR-alpha. It was not a small-molecule kinase inhibitor.
What happened to patients already receiving Lartruvo?
Regulators advised against starting new patients after the negative trial results. Treatment decisions for patients already receiving therapy were handled by treating physicians based on clinical circumstances and available alternatives.
References
-
European Medicines Agency. (2019). EMA recommends suspension of marketing authorisation for Lartruvo. https://www.ema.europa.eu/
-
Eli Lilly and Company. (2017). 2016 annual report. https://investor.lilly.com/
-
Eli Lilly and Company. (2018). 2017 annual report. https://investor.lilly.com/
-
Eli Lilly and Company. (2019). 2018 annual report. https://investor.lilly.com/
-
Food and Drug Administration. (2016). FDA approves Lartruvo for soft tissue sarcoma. https://www.fda.gov/
-
Food and Drug Administration. (2019). FDA statement on the voluntary withdrawal of Lartruvo. https://www.fda.gov/
-
Food and Drug Administration. (2020). Withdrawal of approval of new drug application for Lartruvo. Federal Register. https://www.federalregister.gov/
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009. Public Law 111-148, §7002. https://www.congress.gov/